BDBM683795 6-(2-{[(2R,7aR)-2- fluoro-hexahydro- 1H-pyrrolizin- 7a-yl]methoxy}-4- [(1S,6R)-3,9- diazabicyclo[4.2.1] nonan-3-yl]-8- fluoroquinazolin-7- yl)-4-methyl-5- (trifluoromethyl)pyr- idin-2-amine::US20240217982, Example 12-2

SMILES Cc1cc(N)nc(-c2ccc3c(nc(OC[C@]45CCCN4C[C@H](F)C5)nc3c2F)N2CC[C@H]3CC[C@@H](C2)N3)c1C(F)(F)F

InChI Key InChIKey=OTIFHIDNZDREIZ-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 683795   

TargetGTPase KRas [G12D](Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM683795(US20240217982, Example 12-2 | 6-(2-{[(2R,7aR)-2- f...)
Affinity DataIC50: 330nMAssay Description:Recombinant GDP-loaded KRAS G12D (20 nM) was treated with compound at room temperature for 20 minutes in assay buffer (10 mM Hepes pH 7.4, 150 mM NaC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/11/2024
Entry Details
Go to US Patent